Lidiya Stavitskaya

United States Food and Drug Administration — United States

Computer Science · Physical Sciences

17h-index1.0kcitations35works1.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Computational Drug Discovery Methods(17), Carcinogens and Genotoxicity Assessment(12), Receptor Mechanisms and Signaling(11), Neuropeptides and Animal Physiology(9), Pharmacological Receptor Mechanisms and Effects(7)

Publications35 total

Membrane Permeability Drives the Extreme Potency of Fentanyl
JACS Au·2026Open Access
Evaluation of the Relationship between Vesicular Monoamine Transporter 2 (VMAT2) Inhibition and Neurologic Adverse Events in Approved Drugs
ACS Pharmacology & Translational Science·2025Open Access
Membrane Permeability Drives the Extreme Potency of Fentanyl but not Isotonitazene
2025Open Access
A putative binding model of nitazene derivatives at the μ-opioid receptor
Neuropharmacology·2025· 5 citedOpen Access
Novel (Q)SAR models for prediction of reversible and time-dependent inhibition of cytochrome P450 enzymes
Frontiers in Pharmacology·2025· 4 citedOpen Access
Quantitative Structure–Activity Relationship Models to Predict Cardiac Adverse Effects
Chemical Research in Toxicology·2024Open Access
A Putative Binding Model of Nitazene Derivatives at the <i>μ</i> -Opioid Receptor
2024· 1 citedOpen Access
Machine Learned Classification of Ligand Intrinsic Activities at Human μ-Opioid Receptor
ACS Chemical Neuroscience·2024· 3 citedOpen Access
Machine Learned Classification of Ligand Intrinsic Activities at Human <i>µ</i> -Opioid Receptor
2024· 1 citedOpen Access
Structure–Kinetics Relationships of Opioids from Metadynamics and Machine Learning Analysis
Journal of Chemical Information and Modeling·2023· 15 citedOpen Access
Structure-Kinetics Relationships of Opioids from Metadynamics and Machine Learning
2023· 1 citedOpen Access
New science, drug regulation, and emergent public health issues: The work of FDA’s division of applied regulatory science
Frontiers in Medicine·2023· 23 citedOpen Access
Development of QSAR models to predict blood-brain barrier permeability
Frontiers in Pharmacology·2022· 33 citedOpen Access
Current status and future directions for a neurotoxicity hazard assessment framework that integrates in silico approaches
Computational Toxicology·2022· 37 citedOpen Access
In silico approaches in organ toxicity hazard assessment: Current status and future needs for predicting heart, kidney and lung toxicities
Computational Toxicology·2021· 41 citedOpen Access
Evaluating kratom alkaloids using PHASE
PLoS ONE·2020· 54 citedOpen Access
Development of improved QSAR models for predicting the outcome of the in vivo micronucleus genetic toxicity assay
Regulatory Toxicology and Pharmacology·2020· 20 citedOpen Access
Transitioning to composite bacterial mutagenicity models in ICH M7 (Q)SAR analyses
Regulatory Toxicology and Pharmacology·2019· 32 citedOpen Access
Genetic toxicology in silico protocol
Regulatory Toxicology and Pharmacology·2019· 78 citedOpen Access
Assessing the Structural and Pharmacological Similarity of Newly Identified Drugs of Abuse to Controlled Substances Using Public Health Assessment via Structural Evaluation
Clinical Pharmacology & Therapeutics·2019· 21 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Naomi L. Kruhlak(17), Kevin P. Cross(12), Glenn J. Myatt(10), Alexander Amberg(8), Laura Custer(7), Masamitsu Honma(7), Michelle Kenyon(7), Andrew Teasdale(7), Angela White(7), Joerg Wichard(7), Jana Shen(7), Lisa Beilke(6), Jacky Van Gompel(6), James Harvey(6), Robert A. Jolly(6), Marlene T. Kim(6), Penny Leavitt(6), Donald P. Quigley(6), Lennart T. Anger(5), Joel P. Bercu(5)